Crossmark

18F-fluciclovine PET/CT to distinguish radiation necrosis from tumor progression for brain metastases treated with radiosurgery: results of a prospective pilot study

Crossref DOI link: https://doi.org/10.1007/s11060-023-04377-5

Published Online: 2023-06-21

Published Print: 2023-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tom, Martin C.

DiFilippo, Frank P.

Jones, Stephen E.

Suh, John H.

Obuchowski, Nancy A.

Smile, Timothy D.

Murphy, Erin S.

Yu, Jennifer S.

Barnett, Gene H.

Angelov, Lilyana

Mohammadi, Alireza M.

Huang, Steve S.

Wu, Guiyun

Johnson, Scott

Peereboom, David M.

Stevens, Glen H. J.

Ahluwalia, Manmeet S.

Chao, Samuel T.
Funding

Funding for this research was provided by:

Cleveland Clinic Department of Radiation Oncology

Lerner Research Institute, Cleveland Clinic (RPC 326)

Cleveland Clinic Imaging Institute

Blue Earth Diagnostics
License Information

Text and Data Mining valid from 2023-06-21

Version of Record valid from 2023-06-21
More Information

Article History

Received: 14 May 2023

Accepted: 16 June 2023

First Online: 21 June 2023

Declarations

:

: MCT: Honoraria from ViewRay. Institutional research funding from Blue Earth Diagnostics Ltd. Personal fees from Elsevier. FPD: None. SEJ: None. JHS: Scientific advisory board for and consulting fees from Philips, Novocure. Leadership role with American Board of Radiology, International Radiosurgery Research Foundation, International Stereotactic Radiosurgery Society. NAO: Grants or contracts from Quantitative Imaging Biomarker Alliance. Honoraria from NCI Clinical Imaging Steering committee and ECOG-ACRIN DBMB. TDS: None. ESM: None. JSY: None. GHB: Monteris Medical, Inc. Plymouth, Minnesota. LA: None. AMM: None. SSH: None. GW: None. SJ: None. DMP: None. GHJS: None. MSA: Receipt of grants/research supports: Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, Merck. Receipt of honoraria or consultation fees: Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen, Tocagen, Voyager Therapeutics, Viewray, AnHeart Therapeutics, Caris Lifesciences, Theraguix, Pyramid biosciences. Scientific advisory board: Modifi bio, Pyramid Biosciences, Cairn Therapeutics, Bugworks. Stock shareholder: Doctible, Mimivax, Cytodyn, MedInnovate Advisors LLC. STC: Honoraria from Varian Medical Systems and Blue Earth Diagnostics. Travel support from Blue Earth Diagnostics.

Document is current

Any future updates will be listed below